EPI-002
EPI-002
EPI-002 is a second-generation antiandrogen that has been studied for its potential use in the treatment of prostate cancer. It is a derivative of EPI-001, which was the first compound identified in the EPI series. EPI-002 works by inhibiting the androgen receptor (AR), a critical driver of prostate cancer progression.
Mechanism of Action[edit | edit source]
EPI-002 functions by binding to the androgen receptor at a site distinct from the ligand-binding domain. This unique mechanism allows it to inhibit the AR even in cases where the receptor has become resistant to other forms of antiandrogen therapy, such as enzalutamide and abiraterone. By preventing the AR from activating target genes, EPI-002 can effectively reduce the growth and proliferation of prostate cancer cells.
Development and Research[edit | edit source]
EPI-002 is part of a broader class of drugs known as AR N-terminal domain inhibitors. These inhibitors are designed to target the N-terminal domain of the AR, which is essential for its transcriptional activity. The development of EPI-002 and related compounds represents a significant advancement in the treatment of castration-resistant prostate cancer (CRPC), a form of the disease that no longer responds to traditional androgen deprivation therapy.
Clinical Trials[edit | edit source]
As of the latest updates, EPI-002 has undergone preclinical studies demonstrating its efficacy in inhibiting AR activity and reducing tumor growth in animal models. Clinical trials are anticipated to further evaluate its safety and effectiveness in human patients with advanced prostate cancer.
Related Compounds[edit | edit source]
EPI-002 is closely related to other compounds in the EPI series, including EPI-001 and EPI-506. These compounds share a similar mechanism of action but may differ in their pharmacokinetic properties and clinical efficacy.
See Also[edit | edit source]
- Prostate cancer
- Androgen receptor
- Castration-resistant prostate cancer
- Androgen deprivation therapy
- Enzalutamide
- Abiraterone
- EPI-001
- EPI-506
References[edit | edit source]
External Links[edit | edit source]
-
 | This hospital-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
